+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antiobesity Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5319158
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Norgine B.V.
  • Novo Nordisk A/S
Antiobesity Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global antiobesity drugs market as it emerges from the COVID-19 shut down.



Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the antiobesity drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antiobesity Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx); OTC Drugs
3) By Medication: Monotherapies; Polytherapies

Companies Mentioned: F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Boehringer Ingelheim GmbH; Pfizer Inc; Merck & Co. Inc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Antiobesity Market

What is the estimated value of the Global Antiobesity Market?

The Global Antiobesity Market was estimated to be valued at $2.4 billion in 2021.

What is the growth rate of the Global Antiobesity Market?

The growth rate of the Global Antiobesity Market is 22.6%, with an estimated value of $5.4 billion by 2025.

What is the forecasted size of the Global Antiobesity Market?

The Global Antiobesity Market is estimated to be worth $5.4 billion by 2025.

Who are the key companies in the Global Antiobesity Market?

Key companies in the Global Antiobesity Market include F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc.;Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S and Rhythm Pharmaceuticals.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Norgine B.V.
  • Novo Nordisk A/S
1. Executive Summary

2. Anti-obesity Drugs Market Characteristics

3. Anti-obesity Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Anti-obesity Drugs

5. Anti-obesity Drugs Market Size And Growth
5.1. Global Anti-obesity Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Anti-obesity Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Anti-obesity Drugs Market Segmentation
6.1. Global Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Peripherally acting anti obesity drugs
  • Centrally acting anti obesity drugs
6.2. Global Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription Drugs (Rx)
  • OTC Drugs
6.3. Global Anti-obesity Drugs Market, Segmentation By Medication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Monotherapies
  • Polytherapies
7. Anti-obesity Drugs Market Regional And Country Analysis
7.1. Global Anti-obesity Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Anti-obesity Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Anti-obesity Drugs Market
8.1. Asia-Pacific Anti-obesity Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Anti-obesity Drugs Market
9.1. China Anti-obesity Drugs Market Overview
9.2. China Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Anti-obesity Drugs Market
10.1. India Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Anti-obesity Drugs Market
11.1. Japan Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Anti-obesity Drugs Market
12.1. Australia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Anti-obesity Drugs Market
13.1. Indonesia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Anti-obesity Drugs Market
14.1. South Korea Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Anti-obesity Drugs Market
15.1. Western Europe Anti-obesity Drugs Market Overview
15.2. Western Europe Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Anti-obesity Drugs Market
16.1. UK Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Anti-obesity Drugs Market
17.1. Germany Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Anti-obesity Drugs Market
18.4. France Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Anti-obesity Drugs Market
19.1. Eastern Europe Anti-obesity Drugs Market Overview
19.2. Eastern Europe Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Anti-obesity Drugs Market
20.1. Russia Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Anti-obesity Drugs Market
21.1. North America Anti-obesity Drugs Market Overview
21.2. North America Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Anti-obesity Drugs Market
22.1. USA Anti-obesity Drugs Market Overview
22.2. USA Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Anti-obesity Drugs Market
23.1. South America Anti-obesity Drugs Market Overview
23.2. South America Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Anti-obesity Drugs Market
24.1. Brazil Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Anti-obesity Drugs Market
25.1. Middle East Anti-obesity Drugs Market Overview
25.2. Middle East Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Anti-obesity Drugs Market
26.1. Africa Anti-obesity Drugs Market Overview
26.2. Africa Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Anti-obesity Drugs Market Competitive Landscape And Company Profiles
27.1. Anti-obesity Drugs Market Competitive Landscape
27.2. Anti-obesity Drugs Market Company Profiles
27.2.1. F. Hoffmann-La Roche AG,
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. GlaxoSmithKline PLC,
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Boehringer Ingelheim GmbH,
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Pfizer Inc.,
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Merck & Co. Inc.,
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Anti-obesity Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Anti-obesity Drugs Market

30. Anti-obesity Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Norgine B.V.
  • Novo Nordisk A/S
Major players in the anti-obesity drugs market are F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Pfizer Inc.

The global antiobesity market is expected to grow from $1.46 billion in 2020 to $2.4 billion in 2021 at a compound annual growth rate (CAGR) of 64.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.42 billion in 2025 at a CAGR of 22.6%.

The anti-obesity drugs market consists of sales of anti-obesity drugs and related services. This industry includes establishments that produce pharmacological agents that reduce or control overweight.

Obesity is a major health problem worldwide which is caused from leading a sedentary lifestyle and consumption of unhealthy food. Though various anti-obesity drugs have been approved and are available in the USA, European Union, Australia, and Japan to treat obesity and overweight. It has been observed that these drugs have various adverse effects on patients undergoing treatment for obesity. Adverse effects include low blood pressure and blood glucose, incontinence, insomnia, nausea, diarrhea and others. For instance, Sibutramine and its combination drugs sold under various brands was recalled in various countries due to various side effects including heart attack in consumers. These factors restraint the growth of anti-obesity drugs market.

Pharmaceutical industry is witnessing an increase in the number of mergers and acquisition among companies developing drugs for metabolic disorders such as obesity, diabetes and others. This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market. For instance, in 2018, Evotec AG and Novo Nordisk entered into a strategic alliance to be able to discover and develop drug molecules to treat metabolic disorders including obesity, diabetes and other associated disorders.

Obesity is a major public health concern globally. Globally, prevalence rate of obesity is increasing every year. According to WHO, more than 1.9 billion adults over the age of 18 years were overweight of which over 650 million were obese and 38 million children under the age of 5 were overweight or obese in 2019. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity and lack of awareness on the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving market growth.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Merck & Co. Inc.;Takeda Pharmaceuticals Company Limited
  • Eisai Co. Ltd.
  • Novo Nordisk A/S
  • Zafgen
  • Rhythm Pharmaceuticals
  • Zydus Cadila
  • Norgine B.V.
  • Vivus Therapeutics
  • Arena Pharmaceuticals Inc.
  • Orexigen Therapeutics Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll